Sweden Diabetes Market

Moreover, the SMBG, CMG, and Insulin pump segments also hold a significant market share. Driving factors that help to reach this market are the increasing diabetic Population in Sweden, rising awareness among people, increasing per capita healthcare expenditure, and availability of reimbursements.

Competitive Landscape:-

Sweden Diabetes companies include B. Braun Melsungen AG, Eli Lilly and Company, Terumo Corporation, Becton, Dickenson (BD), Novo Nordisk A/S, Ypsomed AG, Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Corp., Dexcom Inc., Roche Diagnostic, and Tandem Diabetes Care.

 In May 2020, Blighter's Artiste service for people living with insulin-treated diabetes will be available to consumers. Customers can quickly sign up directly at the Artiste website.

 In March 2022, Dexcom released G7 first in the U.K. and will expand the launch across Europe throughout 2022. Meanwhile, the CGM system is currently under review by the Food and Drug Administration for an eventual U.S. release.